P79.03 A Phase 3 Study of the PD-1 Inhibitor Retifanlimab (INCMGA00012) Plus Platinum-Based Chemotherapy in 1L mNSCLC: POD1UM-304

Checkpoint inhibitors have significantly improved outcomes in patients with metastatic non-small cell lung cancer (mNSCLC), and are approved as first-line (1L) treatment as monotherapy as well as in combination with platinum-based chemotherapy. Retifanlimab is a an investigational humanized monoclonal anti–programmed death-1 (PD-1) antibody; in the POD1UM-101 phase 1 study (NCT03059823), retifanlimab demonstrated clinical activity and safety profile similar to other currently approved anti PD-1 antibodies in patients with advanced stage NSCLC.